Navigation Links
Halozyme Reports Second Quarter 2012 Financial Results
Date:8/6/2012

  • Revenues for the second quarter of 2012 were $7.8 million, compared to $23.2 million for the second quarter of 2011. Revenues in the second quarter of 2012 primarily consisted of $2 million in annual exclusivity fees and $4.4 million in research and development reimbursements from partners.
  • Research and development expenses for the second quarter of 2012 were $16.1 million, compared with $15.3 million for the second quarter of 2011, primarily due to an increase in compensation costs and manufacturing activities, partially offset by a decrease in clinical trial activities. 
  • Selling, general and administrative (SG&A) expenses for the second quarter of 2012 were $5.6 million, compared to $4.6 million for the second quarter of 2011. The increase for SG&A was due to higher compensation costs during the quarter. 
  • Cash and cash equivalents were $102.0 million as of June 30, 2012, compared with $79.1 million as of June 30, 2011. Net cash used in the second quarter of 2012 was approximately $14.6 million.
  • 2012 cash burn guidance remains unchanged at $55-$60 million.
  •  

    Conference Call
    The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 398418.

    About Halozyme
    Halozyme Therapeutics is a biopharmaceutical compa
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    2. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    4. Halozyme Reports First Quarter 2012 Financial Results
    5. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    6. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2012
    7. Press Ganey Releases Enhanced Improvement Portal with Customized Performance Reports
    8. Isis Reports Financial Results And Highlights For Second Quarter 2012
    9. Champions Oncology Reports Resignation Of Director
    10. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
    11. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/1/2015)... 1, 2015  Research Solutions, Inc. (OTCQB: RSSS), a pioneer ... (STM) information for life science companies, academic institutions, and ... at the LD Micro Invitational being held on June ... Los Angeles . ... June 3rd at 9:30 a.m. Pacific time, with one-on-one ...
    (Date:6/1/2015)... 2015  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today ... as ,nal-IRI, in a Phase 1 investigator-sponsored study at ... Data were presented at the 2015 American Society of ... IL. Results from this study show a ... glioma when given intravenously.  Based in part ...
    (Date:6/1/2015)... 2015 About Pressure Relief ... area and improve the quality life of patients who ... play a significant role in inhibiting the growth and ... to turn or rotate an immobile patient by providing ... overlay, and specialty beds. These devices have the ability ...
    Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3
    ... MOUNTAIN VIEW, Calif., July 20, 2011 Concentric Medical, ... in ischemic stroke patients, today announced the launch of ... the addition of the V 2.0 Soft and V ... of V Series Merci Retrievers® are now approved and ...
    ... DALLAS, July 20, 2011 ,   ... reports,on The Outlook for Pharmaceuticals for BRIC, Central & ... as well,as E7 countries in its store ... market cover the outlook for pharmaceuticals in,emerging E7 countries as ...
    Cached Medicine Technology:Concentric Medical Launches Full Family of Merci Retrievers® in Japan 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 3ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7) 2ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7) 3ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7) 4
    (Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Lynn Lester as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in business. ... professional women, boasting more than 700,000 members and over ... Lynn Lester with this prestigious award,” said NAPW President ...
    (Date:6/1/2015)... 2015 The National Association of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ... Kathy into this exceptional group of professional women,” ...
    (Date:6/1/2015)... (PRWEB) June 01, 2015 Ticket Down announces ... the NBA Western Conference Finals and now will face the ... will be held at the Oracle Arena in Oakland and ... the 2014-15 National Basketball Association season, the Golden State Warriors ... were a team that learned from their playoff failures from ...
    (Date:6/1/2015)... (PRWEB) June 01, 2015 Linda Kincaid, age ... had an irregular heartbeat. At first she thought it was ... out it was much more than that. After going to ... Linda admitted she felt afraid about what might happen to ... million Americans are diagnosed with valve disease each year. Valve ...
    (Date:6/1/2015)... June 01, 2015 Cambia Health ... today a new, interactive Affordable Care Act (ACA) ... The course, called “Affordable Care Act Expert Series, ... the strategic and consultative insights necessary to effectively ... navigate the impacts of the ACA. , The ...
    Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3
    ... May 12 ULURU Inc. (Amex: ULU ),today ... 31,2008., For the quarter ended March 31, 2008, ... $0.03 per share, compared to a net,loss of $847,000, ... 2007.,The first quarter 2008 net loss was impacted by ...
    ... Fish diet to avoid being beaten up, thrown out ... result. , That is the fascinating conclusion of the latest ... of Excellence for Coral Reef Studies and James Cook University, ... team who recently revealed fish use the threat of punishment ...
    ... FRANKLIN, Mass., May 12 PLC Systems Inc.,(AMEX: ... cardiac and vascular medical,device-based technologies, announced today that ... annual meeting of the European,Association of Percutaneous Cardiovascular ... than 11,000 clinicians and,professionals are expected to attend ...
    ... Study finds little more than half of patients were checked, ... News) -- The dangers of high blood pressure are well-known, ... pressure screening in doctor,s offices and a low percentage of ... , The Stanford University School of Medicine study, published in ...
    ... 08:30 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., ... financial results,for the quarter ended March 31, 2008. The Company finished the ... expense related to stock options, compared to a pro forma NOL,of $18.5 ...
    ... MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, ... over the previous eight,months regarding the formation of ... in these negotiations where final written terms have ... to the Company,s very first,product acquisition. It should ...
    Cached Medicine News:Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6Health News:Fish diet to avoid fights 2Health News:PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008 2Health News:PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008 3Health News:PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008 4Health News:High Blood Pressure Still Slipping Past Doctors 2Health News:High Blood Pressure Still Slipping Past Doctors 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 4Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 5Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 6Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 7Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 8Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 9Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 10Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 11Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 12Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 13Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 14Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2
    ... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
    ... Triiodothyronine (T3) is produced primarily by 5-monodeioination ... the thyroid gland, T3 production occurs at ... that for T4. Release of T3 from ... ~5-8 micrograms/day as compared to 80-100 micrograms/day ...
    ... a monomeric protein produced and stored in ... is released from the pituitary into the ... regulatory control of hypothalamic somatostatin (SS) and ... frequency of GH release appears to be ...
    ... monomeric protein produced and stored in somatotrophs ... released from the pituitary into the bloodstream ... control of hypothalamic somatostatin (SS) and GH-releasing ... of GH release appears to be regulated ...
    Medicine Products: